<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940224-0-00058</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective March 28, 1994; written comments, notice of participation, and request for a hearing by March 28, 1994; data, information, and analyses to justify a hearing by April 25, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Parts 436 and 442</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 93N&hyph;0328]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Antibiotic Drugs; Cefadroxil Hemihydrate: Cefadroxil Hemihydrate Capsules and Cefadroxil Hemihydrate Tablets <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the antibiotic drug regulations to provide for the inclusion of accepted standards for a new antibiotic drug, cefadroxil hemihydrate, and the use of the antibiotic drug in two dosage forms, cefadroxil hemihydrate capsules and cefadroxil hemihydrate tablets. The manufacturer has supplied sufficient data and information to establish its safety and efficacy. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective March 28, 1994; written comments, notice of participation, and request for a hearing by March 28, 1994; data, information, and analyses to justify a hearing by April 25, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written comments to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Peter A. Dionne, Center for Drug Evaluation and Research (HFD&hyph;520), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;0335. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA has evaluated data submitted in accordance with regulations promulgated under section 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357), as amended, with respect to a request for approval of a new antibiotic drug, cefadroxil hemihydrate, and its use in two dosage forms, cefadroxil hemihydrate capsules and cefadroxil hemihydrate tablets. The agency has concluded that the data supplied by the manufacturer concerning these antibiotic drugs are adequate to establish their safety and efficacy when used as directed in the labeling and that the regulations should be amended in 21 CFR parts 436 and 442 to provide for the inclusion of accepted standards for these products. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Environmental Impact <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The agency has determined under 21 CFR 25.24(c)(6) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Submitting Comments and Filing Objections <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> This final rule announces standards that FDA has accepted in a request for approval of an antibiotic drug. Because this final rule is not controversial and because when effective it provides notice of accepted standards, FDA finds that notice and comment procedure is unnecessary and not in the public interest. This final rule, therefore, is effective March 28, 1994. However, interested persons may, on or before March 28, 1994, submit comments to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> Any person who will be adversely affected by this final rule may file objections to it and request a hearing. Reasonable grounds for the hearing must be shown. Any person who decides to seek a hearing must file (1) on or before March 28, 1994, a written notice of participation and request for a hearing, and (2) on or before April 25, 1994, the data, information, and analyses on which the person relies to justify a hearing, as specified in 21 CFR 314.300. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. If it conclusively appears from the face of the data, information, and factual analyses in the request for a hearing that no genuine and substantial issue of fact precludes the action taken by this order, or if a request for a hearing is not made in the required format or with the required analyses, the Commissioner of Food and Drugs will enter summary judgment against the person(s) who request(s) the hearing, making findings and conclusions and denying a hearing. All submissions must be filed in three copies, identified with the docket number appearing in the heading of this document and filed with the Dockets Management Branch. <!-- PJG 0012 frnewline --> The procedures and requirements governing this order, a notice of participation and request for a hearing, a submission of data, information, and analyses to justify a hearing, other comments, and grant or denial of a hearing are contained in 21 CFR 314.300. <!-- PJG 0012 frnewline --> All submissions under this order, except for data and information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects in 21 CFR Parts 436 and 442 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Antibiotics. <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 436 and 442 are amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 436_TESTS AND METHODS OF ASSAY OF ANTIBIOTIC AND ANTIBIOTIC_CONTAINING DRUGS  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 436 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 436.215 is amended by alphabetically adding two new entries to the table in paragraph (b) and by adding new paragraph (c)(17) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;436.215  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Dissolution test. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b) * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 5,L1,i1,s40,30,20,20,20 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Dosage form <!-- PJG 007 0150 intable --> 1Dissolution medium  <!-- PJG 007 0150 intable --> 1Rotation rate <!-- PJG ITAG l=11 g=5 f=1 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1 Sampling time(s)  <!-- PJG 007 0150 intable --> 1Apparatus <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> &blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Cefadroxil hemihydrate capsules  <!-- PJG 007 0104 intable --> 900 mL distilled water <!-- PJG 007 0104 intable --> 100  <!-- PJG 007 0104 intable --> 45 min  <!-- PJG 007 0104 intable --> 1 <!-- PJG 0012 frnewline --> Cefadroxil hemihydrate tablets  <!-- PJG 007 0104 intable --> 900 mL distilled water <!-- PJG 007 0104 intable --> 50  <!-- PJG 007 0104 intable --> 30 min  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> &blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;&blank;*&blank;&blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable --> 1Rotation rate of basket or paddle stirring element (revolutions per minute). <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> (c) * * * <!-- PJG 0012 frnewline --> (17)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Cefadroxil hemihydrate <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in paragraph (c)(1) of this section, except use the cefadroxil working standard and measure the absorbance at the absorption peak of approximately 264 nanometers. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 442_CEPHA ANTIBIOTIC DRUGS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3. The authority citation for 21 CFR part 442 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 4. New &sect;442.7 is added to subpart A to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;442.7  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Cefadroxil hemihydrate. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Cefadroxil hemihydrate is 7-[D-2-amino-2( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> p <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hemihydrate. It is so purified and dried that: <!-- PJG 0012 frnewline --> (i) Its potency is not less than 900 micrograms and not more than 1,050 micrograms of cefadroxil activity per milligram on an anhydrous basis.  <!-- PJG 0012 frnewline --> (ii) [Reserved] <!-- PJG 0012 frnewline --> (iii) Its moisture content is not less than 2.4 percent and not more than 4.5 percent. <!-- PJG 0012 frnewline --> (iv) The pH of an aqueous solution containing 50 milligrams per milliliter is not less than 4.0 and not more than 6.0. <!-- PJG 0012 frnewline --> (v) When calculated on an anhydrous basis, its absorptivity at 264 nanometers is not less than 95 percent and not more than 104 percent of that of the cefadroxil standard similarly treated and corrected for potency. <!-- PJG 0012 frnewline --> (vi) It passes the identity test. <!-- PJG 0012 frnewline --> (vii) It is crystalline. <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . It shall be labeled in accordance with the requirements of &sect;432.5 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requests for certification; samples <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . In addition to complying with the requirements of &sect;431.1 of this chapter, each such request shall contain: <!-- PJG 0012 frnewline --> (i) Results of tests and assays on the batch for cefadroxil potency, moisture, pH, absorptivity, identity, and crystallinity.  <!-- PJG 0012 frnewline --> (ii) Samples, if required by the Director, Center for Drug Evaluation and Research: 10 packages, each containing approximately 500 milligrams. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tests and methods of assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Potency <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Use either of the following methods; however, the results obtained from the hydroxylamine colorimetric assay shall be conclusive. <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Microbiological agar diffusion assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.105 of this chapter, preparing the sample for assay as follows: Dissolve an accurately weighed sample in sufficient 1 percent potassium phosphate buffer, pH 6.0 (solution 1), to give a stock solution of convenient  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> concentration. Further dilute an aliquot of the stock solution with solution 1 to the reference concentration of 20 micrograms of cefadroxil per milliliter (estimated).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hydroxylamine colorimetric assay for cefadroxil <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;442.40(b)(1)(ii), except prepare the working standard and sample solutions and calculate the potency of the sample as follows: <!-- PJG 0012 frnewline --> (A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of working standard solutions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Dissolve and dilute an accurately weighed portion of the cefadroxil working standard in sufficient distilled water to obtain a stock solution of convenient concentration. Further dilute an aliquot of this solution with distilled water to a concentration of 1 milligram of cefadroxil per milliliter. <!-- PJG 0012 frnewline --> (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of sample solutions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Dissolve an accurately weighed portion of the sample in sufficient distilled water to obtain a stock solution of convenient concentration. Further dilute an aliquot of this solution with distilled water to a concentration of 1 milligram of cefadroxil per milliliter (estimated). <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Calculate the potency of the sample in micrograms per milligram as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,p9,9/1,g1,t1,s20,2,18 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Micrograms of cefadroxil per milligram  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1= <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X 100 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> W <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X (100&hyph; <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 --> ) <!-- PJG 007 0152 intable -->   <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 --> &blank; <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Absorbance of sample solution;  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Absorbance of working standard solution; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Potency of working standard solution in micrograms per milliliter; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> W <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Milligrams of sample per milliliter of sample solution; and  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Percent moisture content of the sample. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (2) [Reserved] <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Moisture <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.201 of this chapter. <!-- PJG 0012 frnewline --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> pH <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.202 of this chapter, using an  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> aqueous solution containing 50 milligrams per milliliter. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (5)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Absorptivity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Determine the absorbance of the sample and standard solutions in the following manner: Dissolve accurately weighed portions of approximately 50 milligrams each of the sample and standard in 250 milliliters of distilled water. Transfer a 10-milliliter aliquot to a 100-milliliter volumetric flask and dilute to volume with distilled water. Using a suitable spectrophotometer and distilled water as the blank, determine the absorbance of each solution at 264 nanometers. Determine the percent absorptivity of the sample relative to the absorptivity of the standard using the following calculations: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Percent relative absorptivity = [Absorbance of sample X milligrams standard X potency of standard in micrograms per milligram X 10]/[Absorbance of standard X milligrams sample X (100- <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=3 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> )]  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> where:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Percent moisture in the samples. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (6)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Identity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Using the sample and working standard solutions prepared as described in paragraph (b)(5) of this section and a suitable spectrophotometer, record the ultraviolet spectrum from 220 to 340 nanometers. The spectrum of the sample compares qualitatively with that of the cefadroxil working standard. <!-- PJG 0012 frnewline --> (7)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Crystallinity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.203(a) of this chapter. <!-- PJG 0012 frnewline --> 5. New &sect;&sect;442.107, 442.107a, and 442.107b are added to subpart B to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;442.107  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Cefadroxil hemihydrate oral dosage forms. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;442.107a  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Cefadroxil hemihydrate capsules. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Cefadroxil hemihydrate capsules are composed of cefadroxil hemihydrate and one or more suitable and harmless lubricants and diluents enclosed in a gelatin capsule. Each capsule contains cefadroxil hemihydrate equivalent to 500 milligrams of cefadroxil. Its cefadroxil content is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of cefadroxil that it is represented to contain. Its moisture content is not more than 7.0 percent. It passes the dissolution test. The cefadroxil hemihydrate used conforms to the standards prescribed in &sect;442.7(a)(1).  <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . It shall be labeled in accordance with the requirements of &sect;432.5 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requests for certification; samples <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . In addition to complying with the requirements of &sect;431.1 of this chapter, each such request shall contain: <!-- PJG 0012 frnewline --> (i) Results of tests and assays on: <!-- PJG 0012 frnewline --> (A) The cefadroxil hemihydrate used in making the batch for potency, moisture, pH, absorptivity, identity, and crystallinity.  <!-- PJG 0012 frnewline --> (B) The batch for content, moisture, and dissolution.  <!-- PJG 0012 frnewline --> (ii) Samples, if required by the Director, Center for Drug Evaluation and Research: <!-- PJG 0012 frnewline --> (A) The cefadroxil hemihydrate used in making the batch: 10 packages, each containing approximately 500 milligrams. <!-- PJG 0012 frnewline --> (B) The batch: A minimum of 100 capsules. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tests and methods of assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Cefadroxil content <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Use either of the following methods; however, the results obtained from the hydroxylamine colorimetric assay shall be conclusive. <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Microbiological agar diffusion assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.105 of this chapter, preparing the sample for assay as follows: Place a representative number of capsules into a high-speed glass blender jar containing sufficient 1 percent potassium phosphate buffer, pH 6.0 (solution 1), to give a stock solution of convenient concentration. Blend for 3 to 5 minutes. Remove an aliquot and further dilute with solution 1 to the reference concentration of 20 micrograms of cefadroxil per milliliter (estimated). <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hydroxylamine colorimetric assay for cefadroxil <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;442.40(b)(1)(ii), except prepare the working standard and sample solutions and calculate the potency of the sample as follows: <!-- PJG 0012 frnewline --> (A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of working standard solutions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Dissolve and dilute an accurately weighed portion of the cefadroxil working standard in sufficient distilled water to obtain a stock solution of convenient concentration. Further dilute an aliquot of this solution with distilled water to a concentration of 1 milligram of cefadroxil per milliliter. <!-- PJG 0012 frnewline --> (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of sample solutions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Blend a representative number of capsules in a high-speed glass blender jar with sufficient distilled water to obtain a stock solution of convenient concentration. Further dilute an aliquot of this solution with distilled water to a concentration of 1 milligram of cefadroxil per milliliter (estimated). <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Calculate the cefadroxil content as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,p9,9/1,g1,t1,s20,2,18 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Milligrams of cefadroxil per capsule  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1 = <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> d <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X 1,000 X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> n <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 --> &blank; <!-- PJG /ITAG -->  </TABLE>   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Absorbance of sample solution; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Absorbance of working standard solution; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Potency of working standard solution in micrograms per milliliter; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> d <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Dilution factor of the sample;  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> n <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Number of capsules in the sample assayed. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Moisture <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.201 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Dissolution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.215 of this chapter. The quantity Q (the amount of cefadroxil dissolved) is 75 percent within 45 minutes. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;442.107b  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Cefadroxil hemihydrate tablets. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Cefadroxil hemihydrate tablets are composed of cefadroxil hemihydrate and one or more suitable and harmless binders and lubricants, with or without coloring and film-coating substances. Each tablet contains cefadroxil hemihydrate equivalent to 1,000 milligrams of cefadroxil. Its cefadroxil content is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of cefadroxil that it is represented to contain. Its moisture content is not more than 8.0 percent. It passes the dissolution test. The cefadroxil hemihydrate used conforms to the standards prescribed in &sect;442.7(a)(1).  <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . It shall be labeled in accordance with the requirements of &sect;432.5 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requests for certification; samples <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . In addition to complying with the requirements of &sect;431.1 of this chapter, each such request shall contain: <!-- PJG 0012 frnewline --> (i) Results of tests and assays on: <!-- PJG 0012 frnewline --> (A) The cefadroxil hemihydrate used in making the batch for potency, moisture, pH, absorptivity, identity, and crystallinity.  <!-- PJG 0012 frnewline --> (B) The batch for content, moisture, and dissolution. (ii) Samples, if required by the Director, Center for Drug Evaluation and Research: <!-- PJG 0012 frnewline --> (A) The cefadroxil hemihydrate used in making the batch: 10 packages, each containing approximately 500 milligrams. <!-- PJG 0012 frnewline --> (B) The batch: A minimum of 100 tablets. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tests and methods of assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Cefadroxil content <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Use either of the following methods; however, the results obtained from the hydroxylamine colorimetric assay shall be conclusive. <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Microbiological agar diffusion assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.105 of this chapter, preparing the sample for assay as follows: Place a representative number of tablets into a high-speed glass blender jar containing sufficient 1 percent potassium phosphate buffer, pH 6.0 (solution 1), to give a stock solution of convenient concentration. Blend for 3 to 5 minutes. Remove an aliquot and further dilute with solution 1 to the reference concentration of 20 micrograms of cefadroxil per milliliter (estimated). <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hydroxylamine colorimetric assay for cefadroxil <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;442.40(b)(1)(ii), except prepare the working standard and sample solutions and calculate the potency of the sample as follows: <!-- PJG 0012 frnewline --> (A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of working standard solutions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Dissolve and dilute an accurately weighed portion of the cefadroxil working standard in sufficient distilled water to obtain a stock solution of convenient concentration. Further dilute an aliquot of this solution with distilled water to a concentration of 1 milligram of cefadroxil per milliliter. <!-- PJG 0012 frnewline --> (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of sample solutions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Blend a representative number of tablets in a high-speed glass blender jar with sufficient distilled water to obtain a stock solution of convenient concentration. Further dilute an aliquot of this solution with distilled water to a concentration of 1 milligram of cefadroxil per milliliter (estimated). <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Calculate the cefadroxil content as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,p9,9/1,g1,t1,s20,2,18 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Milligrams of cefadroxil per tablet  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1= <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> d <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X 1,000 X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> n <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 --> &blank; <!-- PJG /ITAG -->  </TABLE>   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Absorbance of sample solution; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Absorbance of working standard solution; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Potency of working standard solution in micrograms per milliliter; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> d <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Dilution factor of the sample; and  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> n <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Number of tablets in the sample assayed. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Moisture <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.201 of this chapter. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0141 unknown --> 001(3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Dissolution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.215 of this chapter. The quantity Q (the amount of cefadroxil dissolved) is 75 percent within 30 minutes. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: February 9, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 -->  Stephanie R. Gray, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 -->  Acting Director, Office of Compliance, Center for Drug Evaluation and Research. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;4078 Filed 2&hyph;23&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            